Log in to save to my catalogue

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in l...

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in l...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e4df0207a07b4df791d9fb4bec0b4c62

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated lung cancers focuses fundamentally on targeting KRAS proximal activators or effectors. However, the antitu...

Alternative Titles

Full title

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e4df0207a07b4df791d9fb4bec0b4c62

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e4df0207a07b4df791d9fb4bec0b4c62

Other Identifiers

ISSN

2041-1723

E-ISSN

2041-1723

DOI

10.1038/s41467-023-41828-z

How to access this item